Menomune (Meningococcal Polysaccharide Vaccine) - Summary

MENOMUNE SUMMARY

Menomune^® -A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, for subcutaneous use, is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y and Group W-135. N meningitidis are cultivated with Mueller Hinton agar¹ and Watson Scherp² media. The purified polysaccharide is extracted from the Neisseria meningitidis cells and separated from the media by procedures which include centrifugation, detergent precipitation, alcohol precipitation, solvent or organic extraction and diafiltration. No preservative is added during manufacture.

Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined, is indicated for active immunization against invasive meningococcal disease caused by these serogroups.⁵

Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined may be used to prevent and control outbreaks of serogroup C meningococcal disease.⁵

For evaluation and management of suspected outbreaks, it is recommended that the health-care workers consult the MMWR for guidance.⁵

Routine vaccination is recommended for the following high-risk groups:⁵

1. Deficiencies in late Complement components (C3, C5-C9).
2. Functional or actual asplenia.
3. Persons with laboratory or industrial exposure to N meningitidis aerosols.
4. Travelers to, and residents of, hyperendemic areas such as sub-Saharan Africa. For information concerning geographic areas for which vaccination is recommended, contact CDC at 404-332-4559.

The American College Health Association (ACHA) also recommends that college students consider vaccination to reduce the risk for potentially fatal meningococcal disease.¹⁹

Vaccinations also should be considered for household or institutional contacts of persons with meningococcal disease and for medical and laboratory personnel at risk of exposure to meningococcal disease.

MENOMUNE NEWS HIGHLIGHTS

Published Studies Related to Menomune (Meningococcal Polysaccharide Vaccine)

Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students. [2008.06]

Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. [2008.04.24]

Meningococcal A vaccination response is enhanced by acute stress in men. [2008.02]

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. [2008.01.09]

One arm or two? Concurrent administration of meningococcal C conjugate and hepatitis B vaccines in pre-teens. [2008.01]

more>>

Clinical Trials Related to Menomune (Meningococcal Polysaccharide Vaccine)

Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years [Recruiting]

Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs [Completed]

Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age [Recruiting]

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age [Completed]

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age [Completed]

more>>